Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4054 | Training for Awareness, Resilience, and Action (TARA) Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014777 | Virus Diseases NIH | 0.11 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is an Early Feasibility Study (EFS) investigating the use of the Hemopurifier® in the treatment of SARS-CoV-2 Virus Disease (COVID-19).
Description: Safety and tolerability
Measure: Incidence of treatment emergent adverse events Time: Day 1 (Date of Consent) to Day 28Description: Safety and tolerability with adverse event graded at 2 or higher
Measure: Incidence of device related adverse events Time: Day 1 (Date of Consent) to Day 14Description: Safety and tolerability
Measure: Incidence of serious adverse events Time: Day 1 (Date of Consent) to Day 28Description: Length of ICU stay in days
Measure: Length if Stay in ICU Time: Day 1 (Date of Consent) to Day 28Description: Number of deaths during hospitalization
Measure: In-hospital mortality Time: Day 1 (Date of Consent) to Day 28Description: Number of days without ventilatory support
Measure: Days free of ventilatory dependency Time: Day 1 (Date of Consent) to Day 28Description: Number of days without vasopressor support
Measure: Vasopressor-free days Time: Day 1 (Date of Consent) to Day 28Description: SOFA scoring system predicts the clinical outcome of critically ill patients.
Measure: Sequential Organ Failure Assessment (SOFA) Time: Before first daily filter treatment and after the last daily filter treatment (i.e. 4 days or more)Description: Measures the severity of disease for adult patients admitted to an ICU
Measure: Acute Physiology and Chronic Health Evaluation (APACHE) Time: Before first daily filter treatment and after the last daily filter treatment (i.e. 4 days or more)Description: Measures viral exposure and levels of circulating virus
Measure: SARS CoV-2 RNA levels in plasma and nasopharyngeal samples Time: Before each filter treatment, every 2 hours during filter treatment and immediately after filter discontinuedDescription: Measurement of lymphocytes as there seems to be a correlation with the disease severity and lymphopenia.
Measure: Total lymphocyte count Time: Before first daily filter treatment and after the last daily filter treatment (i.e. at 4 days or more)Description: Measurement of inflammatory marker levels play a role in systemic vasculitis and cytokine mediated coagulation disorders as the principal actors of multi organ failure in patients with severe COVID-19 complication.
Measure: C-reactive protein (CRP), IL-1, IL-6, and TNF alpha Tests Time: Before first daily filter treatment and after the last daily filter treatment (i.e. at 4 days or more)Description: Measurement of D-dimer levels as levels are elevated in patients with COVID-19 and correlate with disease severity, are a reliable prognostic marker for in-hospital mortality.
Measure: D-dimer Time: Before first daily filter treatment and after the last daily filter treatment (i.e. at 4 days or more)Description: Measurement of Troponin-T as high levels of troponin is found in COVID-19 patients.
Measure: Troponin-T Time: Before first daily filter treatment and after the last daily filter treatment (i.e. at 4 days or more)Description: Measures the levels of SARS-CoV-2 RNA captured in the filter
Measure: Evaluation of SARS-CoV-2 RNA levels post-treatment Hemopurifier cartridges Time: Until study completion, 1 week or for the duration of ICU admissionDescription: Measures the levels of viral particles captured in the filter
Measure: Evaluation of viral particle load post-treatment Hemopurifier cartridges Time: Until study completion, 1 week or for the duration of ICU admissionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports